Although novel biomarkers such as circulating tumor DNA (ctDNA) are currently under investigation1, serum carcinoembryonic antigen (CEA) is still the most widely used tumor marker for colorectal cancer (CRC) worldwide2,3. This evidence concerns the gene CEACAM5 and colorectal carcinoma.